Genmab’s 2018 Capital Markets Day
September 26, 2018 01:24 ET
|
Genmab A/S
Media Release Genmab’s 2018 Capital Markets Day taking place today, will also be webcast liveNumber of Genmab internal speakers, including Executive ManagementTopics include updates on products,...
Genmab's Financial Calendar for 2019
September 25, 2018 03:02 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; September 25, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces its financial calendar for 2019 as follows: EVENTDATEPublication of the Annual Report...
Grant of Restricted Stock Units and Warrants to Genmab employees
September 21, 2018 15:16 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; September 21, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 11,770 restricted stock units and...
Genmab to Host Capital Markets Day
September 19, 2018 08:59 ET
|
Genmab A/S
Media Release Review of Genmab’s progress and operationsEvent will take place at Genmab’s R&D Center in Utrecht, the NetherlandsEvent will be webcast live with an archived version available ...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
September 18, 2018 12:16 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; September 18, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 18,414 shares as a consequence of the exercise of employee...
Genmab to Present at Morgan Stanley 16th Annual Global Healthcare Conference
September 06, 2018 09:00 ET
|
Genmab A/S
Media Release Copenhagen, Denmark; September 6, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will give a company update at the Morgan Stanley...
Genmab Announces European Marketing Authorization for DARZALEX® (daratumumab) for Front Line Multiple Myeloma
August 31, 2018 08:35 ET
|
Genmab A/S
Company Announcement DARZALEX approved in Europe in combination with bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myelomaApproval follows positive...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 14, 2018 13:08 ET
|
Genmab A/S
Company Announcement Copenhagen, Denmark; August 14, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 10,726 shares as a consequence of the exercise of...
Major Shareholder Announcement
August 09, 2018 12:18 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S Copenhagen, Denmark; August 9, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 29...
Genmab Announces Financial Results for the First Half of 2018
August 08, 2018 11:02 ET
|
Genmab A/S
August 8, 2018; Copenhagen, Denmark; Interim Report for the First Half of 2018 Highlights USD 943 million in net sales of DARZALEX® (daratumumab), resulting in royalty income of DKK 695 millionU.S....